AOC 1020

DRUG4 trials

Sponsors

Avidity Biosciences Inc., Avidity Biosciences, Inc.

Conditions

Atrophies, FacioscapulohumeralAtrophy, FacioscapulohumeralDystrophies, Facioscapulohumeral MuscularDystrophies, Landouzy-DejerineDystrophy, Facioscapulohumeral MuscularDystrophy, Landouzy-DejerineFMDFMD2

Phase 1

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

CompletedNCT05747924

Avidity Biosciences, Inc.Atrophies, Facioscapulohumeral, Atrophy, Facioscapulohumeral, Dystrophies, Facioscapulohumeral Muscular +24

Start: 2023-04-04End: 2026-03-20Updated: 2026-07-16

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

CompletedCTIS2022-502096-32-00

Avidity Biosciences Inc.Facioscapulohumeral muscular dystrophy (FSHD)

End: 2023-11-29Target: 12Updated: 2023-12-11

Phase 2

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Active, not recruitingNCT06547216

Avidity Biosciences, Inc.Atrophies, Facioscapulohumeral, Atrophy, Facioscapulohumeral, Dystrophies, Facioscapulohumeral Muscular +24

Start: 2024-07-25End: 2030-06-01Target: 84Updated: 2026-07-14

Phase 3

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Not yet recruitingCTIS2025-521012-18-00

Avidity Biosciences Inc.Facioscapulohumeral Muscular Dystrophy (FSHD)

Target: 80Updated: 2025-11-07